Barbara Domayne-Hayman

Barbara Domayne-Hayman

Entrepreneur-in-residence, Francis Crick Institute

---

Barbara has worked on the commercial side of life sciences for over thirty years, first in a large organisation (ICI/Zeneca/AstraZeneca), before transitioning to the entrepreneurial world of biotech. Barbara joined the Francis Crick Institute in January 2018 as Entrepreneur-in-residence, where amongst other things, she co-founded, led and now is Chair of the KQ Labs accelerator, which is focused on start-ups from all over the UK who are making use of data/AI applied to health. She is also Chief Business Officer of Autifony, where she is responsible for strategic partnering, fundraising and commercial aspects of drug development for CNS disorders. Barbara was also Chair of Puridify, a UCL spin-out with a breakthrough biotherapeutics purification technology, which was acquired by GE (now Cytiva) in November 2017. She is a member of the investment committees of the LifeArc Early Ventures Fund, and Cambridge Enterprise Ventures. 

Previously, Barbara was CEO of Stabilitech, and she was Commercial Director at Arrow Therapeutics until the company was acquired by AstraZeneca. Barbara was also Senior Business Development Manager at Celltech. 

Barbara has a BA and D Phil in Chemistry from the University of Oxford, and is a Sloan Fellow from London Business School.